Serum osteoprotegerin levels are not reduced in multiple myeloma patients

Acta Haematologica Polonica

Volumn 34, Issue 1, 2003, Pages 107-114

  Centkowski, Piotr ^a   Kraj, Maria ^a,b   Kruk, Barbara ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b Klinika Hematologiczna IHiT   (Poland)

Author keywords

Multiple myeloma; Osteolytic lesions; Osteoprotegerin

Indexed keywords

BENCE JONES PROTEIN; CYTOKINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BONE DESTRUCTION; BONE RADIOGRAPHY; CANCER STAGING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MULTIPLE MYELOMA; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS;

EID: 0038071564     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-637.
2. Centkowski P, Kraj M, Kruk B. Ocena stȩżenia osteoprotegeryny w surowicy krwi u chorych na szpiczaka plazmocytowego. Acta Haemat Pol 2002; 33 supl. 1: 137.
3. Centkowski P, Kraj M, Kruk B. Serum osteoprotegerin levels are not reduced in multiple myeloma patients. Hematol J 2002; 3 suppl. 1: 323-324.
4. Chen D, Sarikaya NA, Gunn H, i wsp. ELISA methodology for detection of modified osteoprotegerin in clinical studies. Clin Chem 2001; 47: 747-749.
5. Croucher PI, Shipman CM, Lippitt J, i wsp. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98: 3534-3540.
6. Giuliani N, Bataille R, Mancini C, i wsp. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98: 3527-3533.
7. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappa B ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001; 92: 460-470.
8. Honore P, Lauger NM, Sabino MAC, i wsp. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain - related neurochemical reorganization of the spinal cord. Nat Med. 2000; 6: 521-528.
9. Jung K, Lein M, von Hösslin K, i wsp. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin Chem 2001; 47: 2061-2063.
10. Kraj M. Bone disease and bisphosphonates in multiple myeloma. Nowotwory 2001; 51: 28-33.
11. Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, i wsp. Serum syndecan-1, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (BFGF), metalloproteinase-9 (MMP-9) and osteoprotegerin (OPG) in myeloma (MM) patients. Hematol J 2002; 3 suppl. 1: 358-359.
12. Mizuno A, Amizuka N, Irie K, i wsp. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610-615.
13. Morony S, Capparelli C, Sarosi I, i wsp. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61: 4432-4436.
14. Seidel C, Hjertner O, Abildgaard N, i wsp. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269-2271.
15. Simonet WS, Lacey DL, Dunstan CR, i wsp. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 18: 309-319.
16. Szulc P, Hofbauer LC, Heufelder AE, i wsp. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001; 86: 3162-3165.
17. Yano K, Tsuda E, Washida N, i wsp. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14: 518-527.
18. Zhang J, Dai J, Qi Y, i wsp. Osteoprotegerin inhibits prostate cancer-induced osteoelastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235-1244.